| 摘要 |
<p>The present invention provides biologically active proteins that are activatable by peptidase exposure, such as dipeptidase exposure. The biologically active protein may be a recombinant version of a protein factor that is processed from a native precursor molecule in vivo. Upon administration of the recombinant product to a patient in need, the proteins are converted to the active form in the body by endogenous dipeptidase. The design of such products simplifies the manufacturing process, and may provide for additional therapeutic benefits such as improved pharmacokinetics, half-life, and/or safety profile. The present invention further provides methods of treatment with such compounds, as well as methods of production and/or manufacture.</p> |
